Abstract:Hypertension, Ahead of Print. BACKGROUND:Hypoxia-induced pulmonary hypertension (HPH) is a T helper 17 cell response-driven disease, and PD-1 (programmed cell death 1)/PD-L1 (programmed cell death-ligand 1) inhibitor–associated pulmonary hypertension has been reported recently. This study is designed to explore whether the PD-1/PD-L1 pathway participates in HPH via regulating endothelial dysfunction and T helper 17 cell response.METHODS:Lung tissue samples were obtained from eligible patients. Western blotting, immunohistochemistry, and immunofluorescence techniques were used to assess protein expression, while immunoprecipitation was utilized to detect ubiquitination. HPH models were established in C57BL/6 WT (wild-type) andPD-1−/−mice, followed by treatment with PD-L1 recombinant protein. Adeno-associated virus vector delivery was used to upregulate PD-L1 in the endothelial cells. Endothelial cell function was assessed through assays for cell angiogenesis and adhesion.RESULTS:Expression of the PD-1/PD-L1 pathway was downregulated in patients with HPH and mouse models, with a notable decrease in PD-L1 expression in endothelial cells compared with the normoxia group. In comparison to WT mice,PD-1−/−mice exhibited a more severe HPH phenotype following exposure to hypoxia, However, administration of PD-L1 recombinant protein and overexpression of PD-L1 in lung endothelial cells mitigated HPH. In vitro, blockade of PD-L1 with a neutralizing antibody promoted endothelial cell angiogenesis, adhesion, and pyroptosis. Mechanistically, hypoxia downregulated PD-L1 protein expression through ubiquitination. Additionally, both in vivo and in vitro, PD-L1 inhibited T helper 17 cell response through the PI3K (phosphoinositide 3-kinase)/AKT (protein kinase B)/mTOR (mammalian target of rapamycin) pathway in HPH.CONCLUSIONS:PD-1/PD-L1 plays a role in ameliorating HPH development by inhibiting T helper 17 cell response through the PI3K/AKT/mTOR pathway and improving endothelial dysfunction, suggesting a novel therapeutic indication for PD-1/PD-L1–based immunomodulatory therapies in the treatment of HPH.

Research progress of PI3K/Akt/mTOR signal pathway on hypoxic pulmonary hypertension

Autophagic protein LC3B confers resistance against hypoxia-induced pulmonary hypertension.

Research progress of small molecule inhibitors targeting PI3K-Akt-mTOR pathway

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

"Blue Lips":Research Progress in Pulmonary Vascular Remodeling in Hypoxic Pulmonary Hypertension

Progression of the PI3K/Akt signaling pathway in chronic obstructive pulmonary disease

Targeting the PI3K/mTOR pathway in idiopathic pulmonary fibrosis: Advances and therapeutic potential

Research progress on the role of p53 in pulmonary arterial hypertension

Epigenetic regulation of programmed cell death in hypoxia-induced pulmonary arterial hypertension

Mutual inhibitory mechanisms between PPARγ and Hif-1α: implication in pulmonary hypertension.

Hypoxia-inducible factor signaling in pulmonary hypertension.

Unraveling the role of HIF and epigenetic regulation in pulmonary arterial hypertension: implications for clinical research and its therapeutic approach

PD-1/PD-L1 Provides Protective Role in Hypoxia-Induced Pulmonary Vascular Remodeling

Function of pulmonary arterial fibroblasts in hypoxic pulmonary hypertension

Crosstalk between the Akt/mTORC1 and NF-κB signaling pathways promotes hypoxia-induced pulmonary hypertension by increasing DPP4 expression in PASMCs

Hypoxia-induced PINK1/Parkin-mediated mitophagy promotes pulmonary vascular remodeling

PI3K p85α/HIF-1α accelerates the development of pulmonary arterial hypertension by regulating fatty acid uptake and mitophagy

Inflammation and immunity in the pathogenesis of hypoxic pulmonary hypertension

Targeting PI3K/AKT Signaling for Treatment of Idiopathic Pulmonary Fibrosis

mTOR in the Development of Hypoxic Pulmonary Hypertension Associated with Cardiometabolic Risk Factors

SIRT1 promotes pulmonary artery endothelial cell proliferation by targeting the Akt signaling pathway